The global neuropathic pain market size was valued at USD 8.82 billion in 2024 and is projected to grow from USD 9.38 billion in 2025 to USD 13.86 billion by 2033, exhibiting a CAGR of 5.0% during the forecast period (2025-2033).
Neuropathic pain is a chronic condition caused by damage or dysfunction of the nervous system. It differs from nociceptive pain caused by tissue injury or inflammation. Neuropathic pain can result from various conditions, including diabetes, multiple sclerosis, spinal cord injuries, infections, chemotherapy-induced nerve damage, and postherpetic neuralgia. It often presents as burning, stabbing, or electric shock-like sensations and can severely impact the patient’s quality of life.
The global neuropathic pain market is witnessing significant growth, mainly owing to the increasing prevalence of diabetic neuropathy, post-herpetic neuralgia, multiple sclerosis, and chemotherapy-induced neuropathy disorders. It results from nerve damage or dysfunction, which may be chronic and require long-term management. The market consists of drug therapies, including anticonvulsants, antidepressants, and NSAIDs, and non-drug-based therapies, including neurostimulation, TENS, and acupuncture methods. Also, advances in neuromodulation techniques and AI-based ache monitoring will further boost innovation in treatments.
Furthermore, the increasing demand for personalized ache management treatments, driven by the shift towards opioid alternatives and digital therapeutics, is shaping a strong growth trend in the market. According to the study conducted by Springer Nature Limited, women reported higher levels of neuropathic pain post-spinal injury than men due to differences in ache perception, hormonal influences, and variations in nerve regeneration and inflammatory responses. This rising prevalence among women is driving increased demand for advanced treatments, thereby boosting market growth.
The graph below shows the global demographic distribution of neuropathic pain following spinal injury in males and females in 2023.
Source: Straits Research, Springer Nature Limited
A shift towards non-opioid therapies for neuropathic pain to prevent opioid addiction in patients. Additionally, due to the global opioid crisis, manufacturers have put significant efforts into developing non-opioid formulations for neuropathic pain.
For instance, in July 2022, Vertex Pharmaceuticals started the late-stage development of VX-548, NA1V1.8 Inhibitor, in clinical trials for treating acute and neuropathic pain. This new non-opioid regimen aims to deliver optimal analgesia while avoiding standard opioids' destructive potential.
This shift to a non-opioid therapy, driven by regulatory and safety warnings related to the ongoing opioid crisis, will further boost the market growth.
Personalized pain management is growing as a significant trend in the market, tailoring treatment to an individual's genetic profile, ache sensitivity, and medication response. Research breakthroughs in pharmacogenomics and biomarkers make it possible for healthcare professionals to develop target-specific treatments, thus improving efficiency.
For instance, in April 2023, in the European Journal of Pain, a published paper discussed the genetic and neuroimaging biomarkers predicting an individual's response to treatments.
Such personalized approaches in neuropathic pain enhance market growth by enabling more accurate and effective treatments.
Diabetic neuropathy is a frequent complication of diabetes characterized by damage to nerves due to high levels of blood sugar. The increasing prevalence of diabetic neuropathy implies a demand for better treatment options for diabetes that specifically address neuropathic ache in diabetic patients.
For instance, in October 2022, a research publication in Frontiers in Neurology added that diabetic peripheral neuropathy is one of the leading diabetes complications and necessitates more focused research and innovative treatments for pain management.
This growing prevalence of diabetic complications and demand for treatment that better impacts neuropathic ache in a diabetic patient's life. Additionally, advancements in neuromodulation techniques have induced considerable growth in the market. With increasing research on neurostimulation therapies and innovative technology development in devices, neuromodulation has surfaced as a better treatment modality for managing neuropathic pains.
The high cost of treatment and advanced therapies for neuropathic pain remains a significant barrier to access. Treatments such as spinal cord stimulation (SCS), neurostimulation devices, and novel pharmacological agents often carry substantial upfront costs. These treatments may be inaccessible to patients in regions with poor insurance coverage or for those from lower-income backgrounds.
In addition, certain innovative medications (e.g., biologics and gene therapies) are priced at a premium, further restricting access. High treatment costs thus present a significant challenge to global market growth, particularly in developing regions with limited healthcare funding.
The growing adoption of digital health technologies presents a significant opportunity for improving ache management. These technologies include mobile health applications, wearable devices, telemedicine, and remote patient monitoring that help patients track their symptoms, receive real-time feedback, and access specialized care from remote locations. Such innovations enhance patient engagement and make personalized pain management more accessible and convenient.
This growing demand for digital health solutions presents a lucrative market opportunity for neuropathic pain.
Study Period | 2021-2033 | CAGR | 5.0% |
Historical Period | 2021-2023 | Forecast Period | 2025-2033 |
Base Year | 2024 | Base Year Market Size | USD 8.82 billion |
Forecast Year | 2033 | Forecast Year Market Size | USD 13.86 billion |
Largest Market | North America | Fastest Growing Market | Asia-Pacific |
North America dominates the global neuropathic pain market due to the increasing prevalence of diseases like diabetes, multiple sclerosis, and cancer. Also, the region is boosted by advanced healthcare infrastructure, facilities, a vast patient population, and access to advanced treatments such as drug and non-drug-based therapies. Further, the market's growth is driven by increasing R&D and the development of new therapeutic and supportive regulatory frameworks within the U.S., which boosts the market in the region.
Asia-Pacific is expected to show the fastest growth throughout the forecast period because of the growing prevalence of neuropathic pain disorders, especially diabetic neuropathy, in countries such as India, China, and Japan. Also, the market growth is attributed to factors including developing health infrastructures, growing initiatives of government policies toward ensuring easy accessibility for health services, and improving treatments provided for patients by healthcare. The significant investment in health care and the availability of advanced medical technology in China and India has led to a substantial growth opportunity in the market. This growth is further influenced by the rising awareness of neuropathic ache as well as the adoption of non-opioid therapies.
The global market is experiencing dynamic growth and diversification, with each country contributing uniquely to advancing this transformative field.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global neuropathic pain market is segmented by type, treatment, route of administration, and distribution channel.
The peripheral neuropathy segment dominates the global market due to the increasing prevalence of diabetes, alcohol addiction, and chemotherapy-related damage in peripheral systems. It is the most common form of neuropathic pain, leading to demand among patients for both pharmacological treatments as well as non-pharmacological therapy.
For instance, in November 2022, WHO stated that diabetes affects more than 400 million people globally, and a vast number of patients suffer from diabetic peripheral neuropathy, thus making the peripheral neuropathy section quite the dominant segment in the market.
The drug-based treatment segment dominates the global market due to the rising access and usage of pharmaceutical methods developed to manage neuropathic pain and its effectiveness in alleviating ache related to conditions such as diabetic neuropathy.
For instance, in September 2022, a study released in the Journal of Pain Research underscored the effectiveness of pregabalin and duloxetine for treating different neuropathic pain conditions, thus highlighting the prevalence of drug-based therapies in the market.
The oral segment dominates the global market due to the convenience, simplicity, and easier availability of the drug in the form of a tablet or any other oral presentation. Patients prefer the same drugs because no equipment or special procedures are needed; hence, it is cost-effective and easily accessed. Oral is also selected as most of these drugs, like pregabalin duloxetine, have an oral prescription for the cure of neuropathic pain.
The hospital pharmacies segment dominates the global market as they are more likely to gain direct access to patients admitted into hospitals with varying neurological conditions and surgical interventions. In most acute cases, such as patients post-surgery or under treatment for cancer, hospital pharmacy plays a vital role in handling patients who suffer from intense diabetic neuropathy. Thus, hospitals offer a comprehensive scope of treatment, which covers the use of medications and their substitutes in the form of neuromodulation therapies, among others.
Key players in the industry are focused on adopting key business strategies, such as strategic collaborations, product approvals, acquisitions, and product launches, to gain a strong foothold in the market.
Azurity Pharmaceuticals, Inc.: An emerging player in the neuropathic pain market
Azurity Pharmaceuticals, Inc. is a pharmaceutical company based in the United States that manufactures and markets innovative treatments for patients, especially those in neurology and rare diseases.
Recent developments by Azurity Pharmaceuticals, Inc.:
In April 2023, Azurity Pharmaceuticals, Inc. announced that the U.S. FDA approved their NYMALIZE (nimodipine) oral solution, aimed at improving the delivery of nimodipine for patients with neurological conditions, including those susceptible to neuropathic pain.
January 2025- Vertex Pharmaceuticals received FDA approval for suzetrigine, marketed as Journavx, marking the first new non-opioid pain medication in over two decades. Suzetrigine functions by targeting specific sodium channels associated with pain neurons, offering an alternative to traditional opioids.
As per our analyst, the global market is poised for significant growth, primarily driven by the increasing prevalence of diabetic neuropathy and postherpetic neuralgia and in chemotherapy-induced peripheral neuropathy conditions. Additionally, the non-opioid alternative treatments due to the opioid-related crisis and research into neuromodulation procedures, non-opioid therapeutics, as well as highly personalized approaches are on the rise.
Additionally, advances in digital solutions for health and wearable devices have improved treatment, monitoring, and outcomes for such patients, advancing the market significantly. Furthermore, increasing healthcare access and general awareness, focusing primarily on emerging economies, will drive the market in the future.